Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.

We have shown previously that tumor cell resistance to cisplatin is associated with elevated intracellular levels of glutathione, which is accomplished at least in part by increased expression of the heavy subunit of gamma-glutamylcysteine synthetase (gamma-GCS). To investigate the mechanism by which gamma-GCS expression is elevated, we have examined four related human ovarian cancer cell lines with increasing cisplatin resistance. Relative amounts of steady-state gamma-GCS mRNA in CP70, C30, and C200 were 4.8, 6.0, and 10.6, respectively, compared to the parental A2780 cell line, and a proportional increase in the transcriptional rate but not RNA stability was demonstrated. In contrast, no increase in mRNA for the gamma-GCS light subunit was found. To determine the mechanism of upregulation of this mRNA, we have cloned the promoter of the gene that encodes the heavy subunit of gamma-GCS. This region contains AP-1, NF-kappa B, XRE, AP-2, EpRE, CAAT, and TATA box elements upstream of the transcription initiation site and two MREs between this site and the start codon for the protein. Using gel mobility shift assays, we have found nuclear extract binding activity to the AP-1 response element to be closely associated with the level of gamma-GCS gene expression. A supershift assay showed that the AP-1 DNA-binding complexes are predominantly formed by dimers of JUN family members. Consistent with this finding, the expression of c-JUN was found to be elevated in the resistant cells. In contrast to AP-1 binding, AP-2 and NF-kappa B binding were inversely related to resistance. Furthermore, we have examined a partial revertant of the C200-resistant cells, which shows lower glutathione levels, and found decreased gamma-GCS expression associated with decreased AP-1 binding activity.

[1]  P. Borst,et al.  Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Mulcahy,et al.  Transcriptional up-regulation of gamma-glutamylcysteine synthetase gene expression in melphalan-resistant human prostate carcinoma cells. , 1994, Molecular pharmacology.

[3]  T. Curran,et al.  Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia. , 1994, Molecular and cellular biology.

[4]  K. Laderoute,et al.  Regulation of c-jun expression during hypoxic and low-glucose stress , 1994, Molecular and cellular biology.

[5]  R. Ozols,et al.  Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. , 1994, Biochemical pharmacology.

[6]  P. O'dwyer,et al.  Interaction of heat and hypoxia in modulating transcription of DT diaphorase in human colon adenocarcinoma cells. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[7]  H. Frierson,et al.  Human Ovarian Tumors Express γ-Glutamyl Transpeptidase , 1994 .

[8]  S. Bergelson,et al.  Intracellular glutathione levels regulate Fos/Jun induction and activation of glutathione S-transferase gene expression. , 1994, Cancer research.

[9]  R. Ozols,et al.  Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. , 1993, Cancer research.

[10]  G. Meersma,et al.  Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. , 1992, Cancer research.

[11]  R. Davis,et al.  Characterization of high mobility group protein binding to cisplatin-damaged DNA. , 1992, Biochemical and biophysical research communications.

[12]  G. Wilding,et al.  Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. , 1992, Cancer research.

[13]  A. Godwin,et al.  High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Kashani-Sabet,et al.  The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas. , 1992, Advances in enzyme regulation.

[15]  L. Kèlland,et al.  The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. , 1991, British Journal of Cancer.

[16]  M. Karin,et al.  Rapid and preferential activation of the c-jun gene during the mammalian UV response , 1991, Molecular and cellular biology.

[17]  R. Tjian,et al.  Analysis of the DNA-binding and activation properties of the human transcription factor AP-2. , 1991, Genes & development.

[18]  B. Hill,et al.  An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumour agents shown by a range of human tumour cell lines. , 1990, Biochemical pharmacology.

[19]  T. Hunter,et al.  Oncogene jun encodes a sequence-specific trans- activator similar to AP-1 , 1988, Nature.

[20]  B. Spiegelman,et al.  Common DNA binding site for Fos protein complexesand transcription factor AP-1 , 1988, Cell.

[21]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[22]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .